Trial Profile
A novel high-dose 1 g mesalamine suppository (salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2011
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative proctitis
- Focus Therapeutic Use
- 09 Mar 2011 New trial record